Similarly, a study in NSCLC patients treated with anti-PD-1/PD-L1 by sequencing peripheral PD-1+ CD8+ T cells TCR-β CDR3 region with NGS showed that higher repertoire similarities between pretreatment and 4–6 weeks post-treatment samples were significantly associated with better clinical outcomes [40]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.